Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rodney J Hicks

Showing results (351-360 of 471) with videos related to

Pageof 48
Sort By:
European Journal of Nuclear Medicine and Molecular Imaging|June 13, 2019
Characteristics and outcomes of therapy-related myeloid neoplasms after peptide receptor radionuclide/chemoradionuclide therapy (PRRT/PRCRT) for metastatic neuroendocrine neoplasia: a single-institution seriesIsaac Goncalves, Kate Burbury, Michael Michael, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|July 17, 2013
18F-flumazenil: a γ-aminobutyric acid A-specific PET radiotracer for the localization of drug-resistant temporal lobe epilepsyLucy Vivash, Marie-Claude Gregoire, Eddie W Lau, et al.
Molecular Imaging and Biology|June 19, 2025
Poor Diagnostic Performance of the Melanin-Binding Tracer [18 F]MEL050 in Human Melanoma Indicates Biological HeterogeneityRobert E Ware, Damien Kee, Peter Roselt, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|October 17, 2020
Therapeutic Efficacy of a Bivalent Inhibitor of Prostate-Specific Membrane Antigen Labeled with <sup>67</sup>CuLachlan E McInnes, Carleen Cullinane, Peter D Roselt, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|March 21, 2006
A prospective study to evaluate the impact of FDG-PET on CT-based radiotherapy treatment planning for oesophageal cancerTrevor Leong, Craig Everitt, Kally Yuen, et al.
NPJ Precision Oncology|April 8, 2022
Imaging immunity in patients with cancer using positron emission tomographyFiona Hegi-Johnson, Stacey Rudd, Rodney J Hicks, et al.
European Journal of Nuclear Medicine and Molecular Imaging|February 12, 2009
In-vivo imaging characteristics of two fluorinated flumazenil radiotracers in the ratStefanie Dedeurwaerdere, Marie-Claude Gregoire, Lucy Vivash, et al.
Cancer Imaging : the Official Publication of the International Cancer Imaging Society|May 31, 2019
The role of <sup>18</sup>F-FDG-PET/CT in evaluating retroperitoneal masses -Keeping your eye on the ball!Te-Jui Hung, Luke McLean, Catherine Mitchell, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|June 11, 2016
Does PET SUV Harmonization Affect PERCIST Response Classification?Elske Quak, Pierre-Yves Le Roux, Charline Lasnon, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 29, 2012
Marked, homogeneous, and early [18F]fluorodeoxyglucose-positron emission tomography responses to vemurafenib in BRAF-mutant advanced melanomaGrant A McArthur, Igor Puzanov, Ravi Amaravadi, et al.
Pageof 48

Showing results (351-360 of 471) with videos related to

Sort By:
Pageof 48
European Journal of Nuclear Medicine and Molecular Imaging|June 13, 2019
Characteristics and outcomes of therapy-related myeloid neoplasms after peptide receptor radionuclide/chemoradionuclide therapy (PRRT/PRCRT) for metastatic neuroendocrine neoplasia: a single-institution seriesIsaac Goncalves, Kate Burbury, Michael Michael, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|July 17, 2013
18F-flumazenil: a γ-aminobutyric acid A-specific PET radiotracer for the localization of drug-resistant temporal lobe epilepsyLucy Vivash, Marie-Claude Gregoire, Eddie W Lau, et al.
Molecular Imaging and Biology|June 19, 2025
Poor Diagnostic Performance of the Melanin-Binding Tracer [18 F]MEL050 in Human Melanoma Indicates Biological HeterogeneityRobert E Ware, Damien Kee, Peter Roselt, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|October 17, 2020
Therapeutic Efficacy of a Bivalent Inhibitor of Prostate-Specific Membrane Antigen Labeled with <sup>67</sup>CuLachlan E McInnes, Carleen Cullinane, Peter D Roselt, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|March 21, 2006
A prospective study to evaluate the impact of FDG-PET on CT-based radiotherapy treatment planning for oesophageal cancerTrevor Leong, Craig Everitt, Kally Yuen, et al.
NPJ Precision Oncology|April 8, 2022
Imaging immunity in patients with cancer using positron emission tomographyFiona Hegi-Johnson, Stacey Rudd, Rodney J Hicks, et al.
European Journal of Nuclear Medicine and Molecular Imaging|February 12, 2009
In-vivo imaging characteristics of two fluorinated flumazenil radiotracers in the ratStefanie Dedeurwaerdere, Marie-Claude Gregoire, Lucy Vivash, et al.
Cancer Imaging : the Official Publication of the International Cancer Imaging Society|May 31, 2019
The role of <sup>18</sup>F-FDG-PET/CT in evaluating retroperitoneal masses -Keeping your eye on the ball!Te-Jui Hung, Luke McLean, Catherine Mitchell, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|June 11, 2016
Does PET SUV Harmonization Affect PERCIST Response Classification?Elske Quak, Pierre-Yves Le Roux, Charline Lasnon, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 29, 2012
Marked, homogeneous, and early [18F]fluorodeoxyglucose-positron emission tomography responses to vemurafenib in BRAF-mutant advanced melanomaGrant A McArthur, Igor Puzanov, Ravi Amaravadi, et al.
Pageof 48